Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 21Dermatologic 2Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 4fludarabine phosphate 2fludarabine 2Stem Cell Transplantation 2Platelet Transfusion 2Mycophenolic Acid 2Mesna 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Bone Marrow Transplantation 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2venetoclax 1cedazuridine 1Thiotepa 1Tacrolimus 1Sertraline 1Rituximab 1Observation 1Methotrexate 1Cyclosporine 1Cholecalciferol 1Brentuximab Vedotin 1Biopsy 1Azacitidine 1Aspirin 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × Brentuximab Vedotin × Classical hematology × Clear all
NCT01461538 2016-03-04

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Seagen Inc.

Phase 2 Completed
84 enrolled 20 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡